Compare SLNH & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLNH | MGNX |
|---|---|---|
| Founded | 1961 | 2000 |
| Country | United States | United States |
| Employees | 52 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 220.6M |
| IPO Year | N/A | 2013 |
| Metric | SLNH | MGNX |
|---|---|---|
| Price | $1.69 | $4.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | $5.00 |
| AVG Volume (30 Days) | ★ 19.3M | 618.6K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | $55.83 | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.42 | $1.19 |
| 52 Week High | $5.14 | $4.64 |
| Indicator | SLNH | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 55.21 |
| Support Level | $1.50 | $1.49 |
| Resistance Level | $1.74 | $4.55 |
| Average True Range (ATR) | 0.20 | 0.25 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 70.31 | 47.29 |
Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.